Akademik Veri Yönetim Sistemi
PROSTATE INTERNATIONAL, cilt.13, sa.2, ss.103-106, 2025 (SCI-Expanded, Scopus)
Background: To evaluate the prognostic value of the elimination rate constant K (KELIM), a marker of chemosensitivity, in mCRPC patients treated with docetaxel. Materials and methods: The study included patients who had received first-line docetaxel for mCRPC. The KELIM score was calculated using PSA measurements obtained within the first 100 days of chemotherapy. The patients were divided into two groups based on the KELIM levels: KELIM PSA <1 and KELIM PSA >= 1. The relationship between overall survival (OS) and the KELIM groups was evaluated. Results: A total of 164 patients were included in this study. The median age was 68.1 years (interquartile range (IQR) 62.2-71.1). There were 76 and 88 patients in the KELIM PSA <1 and KELIM PSA >= 1 groups, respectively. The median OS in the KELIM PSA >= 1 group (46.2 months, 95% confidence interval (CI): 38.8-53.6) was found to be longer than in the KELIM PSA <1 group (32.0 months, 95% CI: 23.1-40.9) (P = 0.032). In multivariate analysis, the risk of death was independently higher in the KELIM PSA <1 group than in the KELIM PSA >= 1 group (Hazard Ratio (HR): 1.58, 95% CI: 1.02-2.43, P = 0.037). Conclusions: Higher KELIM scores are positively correlated with improved overall survival in mCRPC patients treated with docetaxel. (c) 2025 The Asian Pacific Prostate Society. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).